Compare PCVX & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | LGND |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.0B |
| IPO Year | 2020 | 1997 |
| Metric | PCVX | LGND |
|---|---|---|
| Price | $60.64 | $311.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $117.30 | ★ $350.92 |
| AVG Volume (30 Days) | ★ 3.7M | 188.1K |
| Earning Date | 11-13-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2886.36 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $141,102,000.00 |
| Revenue This Year | N/A | $8.68 |
| Revenue Next Year | N/A | $30.77 |
| P/E Ratio | ★ N/A | $196.63 |
| Revenue Growth | N/A | ★ 29.48 |
| 52 Week Low | $39.87 | $175.89 |
| 52 Week High | $90.75 | $326.63 |
| Indicator | PCVX | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 55.98 |
| Support Level | $58.85 | $277.97 |
| Resistance Level | $63.08 | $318.30 |
| Average True Range (ATR) | 2.87 | 10.82 |
| MACD | -0.55 | 1.01 |
| Stochastic Oscillator | 15.18 | 62.86 |
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.